{"id":"NCT02959190","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine","officialTitle":"A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-07","primaryCompletion":"2019-08-10","completion":"2019-08-10","firstPosted":"2016-11-08","resultsPosted":"2020-08-24","lastUpdate":"2020-09-29"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]}],"arms":[{"label":"120mg/120mg Galcanezumab - Episodic Migraine (EM)","type":"EXPERIMENTAL"},{"label":"240mg/240mg Galcanezumab - EM","type":"EXPERIMENTAL"},{"label":"Placebo/ 120mg Galcanezumab - EM","type":"EXPERIMENTAL"},{"label":"Placebo/ 240mg Galcanezumab - EM","type":"EXPERIMENTAL"},{"label":"120mg Galcanezumab - CM","type":"EXPERIMENTAL"},{"label":"240mg Galcanezumab - CM","type":"EXPERIMENTAL"}],"summary":"The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.","primaryOutcome":{"measure":"Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Up To 16 Months","effectByArm":[{"arm":"120mg/120mg Galcanezumab - EM","deltaMin":54,"sd":null},{"arm":"240mg/240mg Galcanezumab - EM","deltaMin":56,"sd":null},{"arm":"Placebo/ 120mg Galcanezumab - EM","deltaMin":54,"sd":null},{"arm":"Placebo/ 240mg Galcanezumab - EM","deltaMin":61,"sd":null},{"arm":"120mg Galcanezumab - CM","deltaMin":31,"sd":null},{"arm":"240mg Galcanezumab - CM","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":44,"countries":["Japan"]},"refs":{"pmids":["38581615","33393835"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":58},"commonTop":["Nasopharyngitis","Injection site erythema","Injection site pruritus","Influenza","Dental caries"]}}